Clinical trialNCT05395260WithdrawnEarly phase 1Interventional

FL- 101 Study in Non-Metastatic MIBC

SponsorFlame BiosciencesEnrollment0Muscle Invasive Bladder Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Matthew Galsky, MD
Icahn School of Medicine at Mount Sinai
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Sumanta Kumar Pal, MD
City of Hope Comprehensive Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

FL-101 →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 22 Aug 2022
Primary completion: 28 Nov 2022
Completion: 28 Dec 2022
Last update posted: 19 Aug 2022
Registered enrollment: 0
Registry id: NCT05395260

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.